Search results
Weight-loss drug Zepbound resolves sleep apnea in up to 52% of patients, Lilly says
Reuters via Yahoo News· 3 days agoEli Lilly on Friday said its popular weight-loss drug Zepbound helped resolve moderate to severe...
ADA 2024: Altimmune’s GLP-1 drug shows weight loss potential
Pharmaceutical Technology via Yahoo Finance· 9 hours agoAltimmune has taken another step to claim its share in the growing obesity drug market with new data...
New weight loss drugs, old marketing: Gyms and stores revive classic diet schemes for the Ozempic...
Quartz· 16 hours agoSkyrocketing sales for weight loss drugs known as GLP-1s, first made popular via the diabetes...
As use of drugs for weight loss spikes among teens, data shows girls are using them most
Good Morning America via Yahoo News· 17 hours agoIt wasn't until late last year, after seeing a family member have success taking a medication for ...
Lilly weight-loss drug data spurs selloff in sleep apnea stocks
New Hampshire Union Leader· 7 hours agoThe new class of weight-loss drugs are being tested as cure-alls for everything from knee...
Lilly Weight-Loss Drug Data Spurs Selloff in Sleep Apnea Stocks
Bloomberg· 9 hours agoThe new class of weight-loss drugs are being tested as cure-alls for everything from knee...
The Promise of Weight-Loss Drugs
New York Times· 15 hours agoWhere these drugs might take us — and what that means for medicine. In the past two years, Ozempic has become a synonym for weight loss. Activists argued...
Does Running Really Help You Lose Weight? Here's What Experts Say
Women's Health via Yahoo News· 6 hours agoRunning can help you lose weight when combined with healthy habits and a balanced diet. Here,...
How Lilly is joining Novo in the crusade to circumvent Medicare's block on weight loss drugs
Yahoo Finance· 7 hours agoThe leaders in the business of weight-loss drugs, Novo Nordisk and Eli Lilly, are fighting on a...
ALT Stock Alert: Altimmune Pops on Weight-Loss Drug Findings
InvestorPlace· 10 hours agoThis surge comes after the company released results from a 48-week study of pemvidutide, the firm’s...